Phase Ib Study (GO28440) of Venetoclax with Bendamustine/Rituximab or Bendamustine/Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia

Stilgenbauer, Stephan; Morschhauser, Franck; Wendtner, Clemens‐Martin; Cartron, Guillaume; Hallek, Michael; Eichhorst, Barbara; Kozloff, Mark; A. Giever, Thomas; Lozanski, Gerard; A. Punnoose, Elizabeth; Wang, Jue; Hilger, James; Mobasher, Mehrdad; Salles, Gilles

doi:10.1182/blood.v128.22.4393.4393

Public

Phase Ib Study (GO28440) of Venetoclax with Bendamustine/Rituximab or Bendamustine/Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia

Published in Blood • Dec 2, 2016

Authors:

Stephan Stilgenbauer

Franck Morschhauser

Clemens‐Martin Wendtner

Abstract

Abstract Introduction: The anti-apoptotic protein BCL2 is overexpressed in a number of hematological malignancies, including chronic lymphocytic leukemia (CLL). Venetoclax (VEN) is a selective, oral BCL2 inhibitor with demonstrated activity and an acceptable safety profile both as monotherapy and in...

Subject

Bendamustine

Obinutuzumab

Venetoclax

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!